SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Kos Pharmaceuticals, Inc (KOSP)
An SI Board Since March 1997
Posts SubjectMarks Bans Symbol
118 20 0 KOSP
Emcee:  DD™ Type:  Unmoderated
Introduction Market Data Compact
Kos Pharmaceuticals, Inc went public today @$20 1/4 per share, closing up 1 3/4.

Description:

Kos Pharmaceuticals develops pharmaceuticals to treat chronic cardiovascular and respiratory diseases. The company's cardiovascular products are primarily controlled-release, once-a-day, oral dosage formulations, while its respiratory products are aerosolized inhalation products. The company has developed Niaspan, an oral drug
composed of niacin, for the treatment of multiple lipid disorders which are associated with coronary heart disease. Kos has agreements with Fuisz Technologies for the development of products using a technology developed by Fuisz. The company also sponsors basic research at Tufts University and Boston University.

Any/all constructive commentary is appreciated.

DD
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
118Abbott to Expand Presence in Lipid Management Market With Acquisition of Kos Phakenhott-11/6/2006
117gs: Kos Pharmaceuticals, Inc. (KOSP): Raising EPS on better pricing, softer volumopgcw-8/11/2006
116Skyepharma, Kos agree marketing, distribution deal for Flutiform in US LONDON (nigel bates-5/8/2006
115This first came out on Friday, missed it then. From Merrill: Estimate Change; “tom pope-12/19/2005
114Invitation for a KOSP aficionado: finance.messages.yahoo.com T.i.a. Dew DewDiligence_on_SI-9/11/2005
113NYT. Mention of KOSP and niacin. --------------------------------------------tom pope-6/28/2005
112Merrill: Kos Pharmaceuticals Inc  Company Update; Raising Price Target to $75 tom pope-6/22/2005
111I learned something here. My knee jerk reaction when I read the initial announckenhott-5/5/2005
110Merrill: Price Objective Changes Kos Pharmaceuticals Inc (KOSP, $54.29, C-1-9) tom pope-5/5/2005
109>>WOODCLIFF LAKE, N.J., April 27 /PRNewswire-FirstCall/ -- Barr Pharmaceuttuck-4/27/2005
108It all depends on the terms of the deal and whether it gets approved by the FTC.IRWIN JAMES FRANKEL-3/30/2005
107I have sold this morning after buying a couple of weeks ago. Not sure why such kenhott-3/30/2005
106Barr, Kos in talks over cholesterol drug patent <i> KOSP up about $6</Doc Bones-3/30/2005
105gs: Kos Pharmaceuticals, Inc. EPS (FY Dec) 2004E $1.94, 2005E $2.33 In-Line/Neutmopgcw-12/9/2004
104GS: Kos Pharmaceuticals, Inc. EPS (FY Dec) 2004E $1.67, 2005E $2.32 In-Line/Neutmopgcw-11/11/2004
103Yup. (eom)scaram(o)uche-11/4/2004
102There are some of us reading and appreciating all info posted here. thanks stevsjemmeri-11/4/2004
101URL for the earnings release. Apparently SI won't accept the misspellings iLance Bredvold-11/4/2004
100GS: Kos Pharmaceuticals, Inc. EPS (FY Dec) 2004E $1.67, 2005E $2.32 In-Line/Neutmopgcw-10/31/2004
99GS: Kos Pharmaceuticals, Inc. EPS (FY Dec) 2004E $1.69, 2005E $2.32 In-Line/Neutmopgcw-9/27/2004
98I thought this was old news, but Dow_Jones Newswire just published it: Barr tom pope-6/16/2003
97KOSP KOS Pharma receives approval for Niaspan in the UK (23.70) Co receives ftom pope-6/13/2003
9613:56 ET   KOSP  KOS Pharma reit Outperform at Ryan Beck; taIRWIN JAMES FRANKEL-6/2/2003
95Briefing: 07:26 ET KOSP KOS Pharma downgraded at Deutsche, UBS (24.36) Deutom pope-6/2/2003
94Briefing: 12:21 ET KOSP Short-Squeeze Alert -- KOS Pharma (24.15 +1.06) Istom pope-5/27/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News